Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CaTaCo-Hem
- Development stage
- Preclinical
- Lead developer
- PAI Life Sciences
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
CaTaCo-Hem (Catalysis-Targeted Construct-Haematobium) is a next-generation, 44-kDa recombinant protein subunit vaccine antigen derived from the Schistosoma haematobium calpain ortholog (Sh-p80). Developed by Midwestern University and PAI Life Sciences, it is designed to protect against urogenital schistosomiasis (UGS). CaTaCo-Hem is engineered by deleting certain hydrophobic regions of the full-length 80 kDa Sh-p80 calpain that are not required for enzymatic activity, resulting in a soluble monomer with fewer degradation products and less aggregation when expressed in E. coli. Formulated with proprietary TLR-4 agonist-based adjuvants such as EmT4 or LiT4Q, CaTaCo-Hem-based vaccines have demonstrated robust immunogenicity and efficacy in animal models, inducing high levels of specific IgG antibodies and reducing worm burden, tissue egg burden, and egg viability.
- Other names
- Catalysis-Targeted Construct-Haematobium
Beyond the preview
Go deeper on CaTaCo-Hem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CaTaCo-Hem.